Pioglitazone 30 mg for Insulin Resistance

Phase-Based Progress Estimates
Saint Louis Univeristy, Saint Louis, MOInsulin Resistance+1 MorePioglitazone 30 mg - Drug
18 - 85
What conditions do you have?

Study Summary

This trial looks at whether giving the drug pioglitazone to men with prostate cancer who are also on ADT will help improve insulin resistance.

Eligible Conditions
  • Insulin Resistance
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 6 months

6 months
Insulin signaling
Insulin signaling (Insulin receptor substrate expression in fat tissue)
insulin sensitivity

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

7%Oedema peripheral
5%Upper respiratory tract infection
5%Back pain
5%Pain in extremity
5%Urinary tract infection
2%Acute myocardial infarction
1%Iron deficiency anaemia
1%Cardiopulmonary failure
1%Supraventricular tachycardia
1%Gastric haemorrhage
1%Gastric ulcer
1%Traumatic fracture
1%Squamous cell carcinoma of skin
1%Chronic obstructive pulmonary disease
1%Device related infection
1%Upper gastrointestinal haemorrhage
1%Cholecystitis acute
1%Craniocerebral injury
1%Chronic lymphocytic leukaemia
1%Pleural effusion
1%Pulmonary embolism
1%Hypertensive crisis
1%Peripheral ischaemia
This histogram enumerates side effects from a completed 2013 Phase 3 trial (NCT01183013) in the Lina5Pio30/Lina5Pio30 ARM group. Side effects include: Oedema with 9%, Dizziness with 7%, Oedema peripheral with 7%, Nasopharyngitis with 6%, Hyperglycaemia with 6%.

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

44 Total Participants · 2 Treatment Groups

Primary Treatment: Pioglitazone 30 mg · Has Placebo Group · Phase 2

Experimental Group · 1 Intervention: Pioglitazone 30 mg · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: placebo tablet · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
187 Previous Clinical Trials
38,108 Total Patients Enrolled
1 Trials studying Insulin Resistance
44 Patients Enrolled for Insulin Resistance

Eligibility Criteria

Age 18 - 85 · Male Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is enrollment open for this particular research effort?

"According to the information on clinicaltrials.gov, this research is searching for participants and has been available since December 1st 2021 with edits having taken place as recently as June 30th 2022." - Anonymous Online Contributor

Unverified Answer

What is the usual purpose of administering Pioglitazone 30 mg?

"Pioglitazone 30 mg is typically prescribed to treat diabetes, yet it can also assist patients in tackling diabetic neuralgia and promoting a healthy lifestyle with diet and exercise." - Anonymous Online Contributor

Unverified Answer

Is the age cut-off for participation in this research trial below 30 years of age?

"Those hoping to be included in this clinical trial must fall within the age range of 18-85. The study features 101 studies for minors and 1422 research opportunities for seniors." - Anonymous Online Contributor

Unverified Answer

Is it possible for me to become a participant in this clinical trial?

"To qualify for this clinical trial, potential participants must exhibit insulin resistance and be between 18 to 85 years old. The total number of admitted patients is 44 individuals." - Anonymous Online Contributor

Unverified Answer

How many participants are enrolled in this research endeavor?

"Affirmative. According to the information on clinicaltrials.gov, this medical research was established on December 1st 2021 and is presently seeking 44 participants from a single site. The trial has been recently updated as of June 30th 2022." - Anonymous Online Contributor

Unverified Answer

Does the administration of Pioglitazone 30 mg pose any substantial health risks?

"Our group at Power analyzed the safety of Pioglitazone 30 mg and determined that this Phase 2 trial, which has some evidence supporting its security but no proof for efficacy, deserves a rating of 2." - Anonymous Online Contributor

Unverified Answer

Could you provide a catalog of research projects utilizing Pioglitazone 30 mg?

"Presently, there are 31 clinical trials examining the efficacy of Pioglitazone 30 mg. Of those, 4 have reached Phase 3 status. These studies primarily occur in Lausanne, Vaud; however 69 other locations worldwide are running these same trials." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.